BIOMAT Database Logo BIOMAT Database Logo

Phase I study of oral doxifluridine using two schedules. 1989

P Alberto, and J J Winkelmann, and N Paschoud, and R Peytremann, and A Bruyere, and A Righetti, and G Decoster, and E E Holdener
Division of Oncology, University Hospital, Geneva, Switzerland.

UI MeSH Term Description Entries
D007536 Isomerism The phenomenon whereby certain chemical compounds have structures that are different although the compounds possess the same elemental composition. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Isomerisms
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D005467 Floxuridine An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. FUdR,Fluorodeoxyuridine,5-FUdR,5-Fluorodeoxyuridine,5 Fluorodeoxyuridine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P Alberto, and J J Winkelmann, and N Paschoud, and R Peytremann, and A Bruyere, and A Righetti, and G Decoster, and E E Holdener
Phase I study of two schedules of teroxirone.
May 1987, Cancer treatment reports,
P Alberto, and J J Winkelmann, and N Paschoud, and R Peytremann, and A Bruyere, and A Righetti, and G Decoster, and E E Holdener
Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study.
September 2000, Oncology,
P Alberto, and J J Winkelmann, and N Paschoud, and R Peytremann, and A Bruyere, and A Righetti, and G Decoster, and E E Holdener
A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
January 2016, Cancer chemotherapy and pharmacology,
P Alberto, and J J Winkelmann, and N Paschoud, and R Peytremann, and A Bruyere, and A Righetti, and G Decoster, and E E Holdener
Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules.
January 2016, PloS one,
P Alberto, and J J Winkelmann, and N Paschoud, and R Peytremann, and A Bruyere, and A Righetti, and G Decoster, and E E Holdener
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region.
August 1993, Tumori,
P Alberto, and J J Winkelmann, and N Paschoud, and R Peytremann, and A Bruyere, and A Righetti, and G Decoster, and E E Holdener
Phase I trial of caracemide using bolus and infusion schedules.
April 1987, Cancer treatment reports,
P Alberto, and J J Winkelmann, and N Paschoud, and R Peytremann, and A Bruyere, and A Righetti, and G Decoster, and E E Holdener
Phase I trial of Indicine-N-Oxide on two dose schedules.
June 1983, Cancer,
P Alberto, and J J Winkelmann, and N Paschoud, and R Peytremann, and A Bruyere, and A Righetti, and G Decoster, and E E Holdener
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
May 2003, Oncology (Williston Park, N.Y.),
P Alberto, and J J Winkelmann, and N Paschoud, and R Peytremann, and A Bruyere, and A Righetti, and G Decoster, and E E Holdener
A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer.
August 2005, Cancer chemotherapy and pharmacology,
P Alberto, and J J Winkelmann, and N Paschoud, and R Peytremann, and A Bruyere, and A Righetti, and G Decoster, and E E Holdener
A phase I study of doxifluridine as a five-day stepped-dose continuous infusion.
August 1990, American journal of clinical oncology,
Copied contents to your clipboard!